Structure-based drug design meets the ribosome

• Published in: Biochemical pharmacology Vol. 71; no. 7; pp. 1016 - 1025
• Main Authors: Franceschi, François, Duffy, Erin M.
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 30.03.2006
• Subjects: Anti-Bacterial Agents - chemistry; Anti-Bacterial Agents - pharmacology; Antibacterials; Antibiotics; Computational chemistry; Drug Design; Humans; Molecular Structure; Ribosomes; Ribosomes - chemistry; Ribosomes - drug effects; RNA, Ribosomal - chemistry; RNA, Ribosomal - drug effects; Structure-Activity Relationship; Structure-based drug design; X-ray structure; Computational chemistry; Antibacterials; Structure-based drug design; Antibiotics; X-ray structure; Ribosomes
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2005.12.026

The high-resolution structures of the bacterial ribosomal subunits and those of their complexes with antibiotics have advanced significantly our understanding of small-molecule interactions with RNA. The wealth of RNA structural data generated by these structures has allowed computational chemists to employ a drug discovery paradigm focused on RNA-based targets. The structures also show how target-based resistance affects antibiotics acting at the level of the ribosome. Not only are the sites pinpointed where different classes of antibiotics inhibit protein synthesis, but their orientations, relative dispositions, and unique mechanisms of action are also revealed at the atomic level. Both the 30S and the 50S ribosomal subunits have been shown to be “targets of targets”, offering several adjacent, functionally relevant binding pockets for antibiotics. It is the detailed knowledge of these validated locations, or ribofunctional loci, plus the mapping of the resistance hot-spots that allow the rational design of next-generation antibacterials. When the structural information is combined with a data-driven computational toolkit able to describe and predict molecular properties appropriate for bacterial cell penetration and drug-likeness, a structure-based drug design approach for novel antibacterials shows great promise.